Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Authors:
- Karen A GelmonKaren A Gelmon
- Marc TischkowitzMTMarc Tischkowitz
- Helen MackayHMHelen Mackay
- Kenneth SwenertonKSKenneth Swenerton
- André RobidouxARAndré Robidoux
- Katia TonkinKTKatia Tonkin
- Hal HirteHHHal Hirte
- David HuntsmanDHDavid Huntsman
- Mark ClemonsMCMark Clemons
- Blake GilksBGBlake Gilks
- Rinat YerushalmiRYRinat Yerushalmi
- Euan MacphersonEMEuan Macpherson
Top Cited Papers
- 1 September 2011
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 12 (9) , 852-861
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast CancerNew England Journal of Medicine, 2011
- Triple negative breast cancer: unmet medical needsBreast Cancer Research and Treatment, 2010
- PARP inhibition: PARP1 and beyondNature Reviews Cancer, 2010
- A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitorThe EMBO Journal, 2008
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature, 2008
- Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalitiesBMC Cancer, 2008
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesThe American Journal of Human Genetics, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989